Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Dahuanong Completes ChiNext IPO

publication date: Mar 8, 2011
Guangdong Dahuanong Animal Health Products Co. (DHN), a veterinary products company with a bird flu vaccine, completed its IPO on the ChiNext exchange. DHN placed 67 million shares at a price of 22 RMB, raised 1.5 billion RMB ($228.4 million). The pricing reflected a price/earnings ratio of 51. The company's shares rose a modest 2% in the aftermarket to close at 22.41 RMB per share. More details....

Stock Symbol: (SHE: 300186)     Share this with colleagues:  


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital